TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 0.220nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 0.870nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 0.940nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 1.21nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 1.79nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 3.06nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 3.60nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 3.70nMAssay Description:Inhibition of ENPP1 (unknown origin)More data for this Ligand-Target Pair
Ligand Info
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 3.92nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 4.23nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 4.34nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 4.37nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 4.80nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 4.95nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 5.97nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 6.38nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 6.87nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 7.74nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 8.11nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: 9.80nMAssay Description:Table 1: Assay Buffer: 1 mM CaCl2, 0.2 mM ZnCl2, 50 mM Tris, pH 9.0 Substrate: 1.5 mM Thymidine 5′-monophosphate disodium salt hydrate (Sigma: ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Homo sapiens (Human))
Stingray Therapeutics
US Patent
Stingray Therapeutics
US Patent
Affinity DataIC50: <10nMAssay Description:Assay 1: Test compounds were plated in a 3 dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in...More data for this Ligand-Target Pair